ScholarIQanswers from OpenAlex

SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial

PaperCitations, authors & open-access status

SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial is a paper indexed in ScholarIQ from OpenAlex.

How many citations does SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial have?

ScholarIQcitation count

SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial has 0 citations in the OpenAlex counts ScholarIQ stores.

When was SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial published?

ScholarIQyear

SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial has 2023 year in the ScholarIQ index.

What is the open-access status of SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial?

ScholarIQoa status

SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial has closed oa status in the ScholarIQ index.

What is the DOI of SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial?

ScholarIQdoi

The DOI for SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial is on the source record.

What is the OpenAlex record for SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial?

ScholarIQopenalex

The OpenAlex for SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial